Iganef-3 Tab (Budesonide) 3MG

Budesonide binds to intracellular glucocorticoid receptors, forming a complex that enters the cell nucleus and modulates gene transcription. This suppresses the production of pro‑inflammatory cytokines and promotes anti‑inflammatory proteins, leading to decreased leukocyte infiltration and edema in the gut mucosa.

The dosage of Iganef-3 Tab is individualized by the prescribing clinician based on disease severity, patient weight, and response to therapy. The prescriber determines the appropriate number of tablets and dosing schedule; patients should follow the exact instructions provided on the prescription label.

Budesonide is classified as pregnancy category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies any potential risk. Limited data are available for breastfeeding, and a decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Iganef-3 Tab. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Budesonide has high first‑pass metabolism, resulting in lower systemic exposure compared with conventional oral corticosteroids like prednisone. This profile offers effective local anti‑inflammatory action in the gut while reducing the incidence of systemic side effects such as weight gain, glucose intolerance, and adrenal suppression, making it a preferred option for targeted IBD therapy.

Iganef-3 Tab should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original blister pack or container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Iganef-3 Tab is taken orally, usually with water. It can be taken with or without food, but patients should follow the specific instructions given by their prescriber regarding timing relative to meals to maintain consistent drug absorption.

The most serious risks include adrenal suppression, which can lead to insufficient cortisol production, severe infections due to immunosuppression, and long‑term bone loss (osteoporosis). Patients should be monitored for signs of these conditions, and any concerning symptoms should be reported to a healthcare professional promptly.

Iganef-3 Tab is contraindicated in patients with known hypersensitivity to budesonide or any excipients in the tablet, and in those with systemic fungal infections. Caution is also advised for individuals with uncontrolled infections, severe liver impairment, or those receiving other potent systemic glucocorticoids.